Citations

Clear

9383 citation(s) found for "Thomas, PS".

Views of Recently First-Certified US Child Neurologists on Their Residency Training
Gilbert, Donald L. , Patterson, Marc C. , Pugh, John, Ridel, Keith R., Reynolds, Thomas Q., Valencia, Ignacio , Patterson, Marc

Mayo Clinic

Journal of Child Neurology | January 28, 2013 | Volume: 28 | Issue: 3 | Pages: 332-339

10.1177/0883073812473644 | PMID 23358629 Get It

We surveyed child neurologists first certified in “Neurology with Special Qualification in Child Neurology” by the American Board of Psychiatry and Neurology (ABPN) between 2001 and 2010 using a 24-item questionnaire. Respondents (n = 204, 54% response rate) were between the ages of 30 and 59 years (54% male), and 68% completed adult neurology training in a 10- to 12-month, primarily inpatient block. Sixty-two percent of the sample completed subspecialty fellowship training and 82% currently reported practicing within a hospital or hospital-based/owned clinic. Current practice data showed just 3% provide general neurology services to adults. A majority reported using adult neurology residency training “less than weekly” and believed the ideal model for residency training in diagnosis and management of both common and rare neurologic conditions would involve less time in adult neurology and more time (mean 6 months) in child neurology, most prominently in genetics and developmental and behavioral areas.
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
Goss, Paul E., Budd, G. Thomas , Rabaglio, Manuela , Ansari, Rafat , Johnson, David B. , Tozer, Richard , D’Souza, David , Chalchal, Haji , Spadafora, Silvana , Stearns, Vered , Perez, Edith A. , Liedke, Pedro Emanuel Rubini , Láng, István, Elliott, Catherine, Chapman, Judy-Anne W., Shepherd, Lois E. , Ingle, James N. , Pritchard, Kathleen I. , Ellis, Matthew J. , Sledge, George W. , Gelmon, Karen A. , Chapman, Judy‐Anne W., Stearns, Vered , Rabaglio-Poretti, Manuela

Mayo Clinic

Journal of Clinical Oncology | January 28, 2013 | Volume: 31 | Issue: 11 | Pages: 1398-1404

10.1200/jco.2012.44.7805 | PMID 23358971 Get It

Purpose In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non–cross-resistant with nonsteroidal aromatase inhibitors and is a mild androgen and could prove superior to anastrozole regarding efficacy and toxicity, specifically with less bone loss. Patients and Methods We designed an open-label, randomized, phase III trial of 5 years of exemestane versus anastrozole with a two-sided test of superiority to detect a 2.4% improvement with exemestane in 5-year event-free survival (EFS). Secondary objectives included assessment of overall survival, distant disease–free survival, incidence of contralateral new primary breast cancer, and safety. Results In the study, 7,576 women (median age, 64.1 years) were enrolled. At median follow-up of 4.1 years, 4-year EFS was 91% for exemestane and 91.2% for anastrozole (stratified hazard ratio, 1.02; 95% CI, 0.87 to 1.18; P = .85). Overall, distant disease–free survival and disease-specific survival were also similar. In all, 31.6% of patients discontinued treatment as a result of adverse effects, concomitant disease, or study refusal. Osteoporosis/osteopenia, hypertriglyceridemia, vaginal bleeding, and hypercholesterolemia were less frequent on exemestane, whereas mild liver function abnormalities and rare episodes of atrial fibrillation were less frequent on anastrozole. Vasomotor and musculoskeletal symptoms were similar between arms. Conclusion This first comparison of steroidal and nonsteroidal classes of aromatase inhibitors showed neither to be superior in terms of breast cancer outcomes as 5-year initial adjuvant therapy for postmenopausal breast cancer by two-way test. Less toxicity on bone is compatible with one hypothesis behind MA.27 but requires confirmation. Exemestane should be considered another option as up-front adjuvant therapy for postmenopausal hormone receptor–positive breast cancer.
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease
Yab, Tracy C. , Hussain, Fareeda Taher Nazer, Garrity-Park, Megan, Sandborn, William J. , Loftus, Edward V. , Wolff, B. G., Smyrk, Thomas C. , Zou, Hongzhi , Ahlquist, David A. , Kisiel, John B. , Taylor, William R. , Itzkowitz, Steven H. , Rubin, David T. , Mahoney, Douglas W. , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 24, 2013 | Volume: 37 | Issue: 5 | Pages: 546-554

10.1111/apt.12218 | PMID 23347191 Get It

SummaryBackgroundCurrent approaches to the detection of colorectal neoplasia associated with inflammatory bowel disease (IBD‐CRN) are suboptimal.AimTo test the feasibility of using stool assay of exfoliated DNA markers to detect IBD‐CRN.MethodsThis investigation comprised tissue and stool studies. In the tissue study, gene sequencing and methylation assays were performed on candidate genes using tissue DNA from 25 IBD‐CRNs and from 25 IBD mucosae without CRN. Mutations on p53, APC, KRAS, BRAF or PIK3CA genes were insufficiently informative, but several aberrantly methylated genes were highly discriminant. In the stool study, we evaluated candidate methylated genes (vimentin, EYA4, BMP3, NDRG4) in a prospective blinded study on buffered stools from 19 cases with known IBD‐CRN and 35 age‐ and sex‐matched IBD controls without CRN. From stool‐extracted DNA, target genes were assayed using quantitative allele‐specific real‐time target and signal amplification method.ResultsIBD‐CRN cases included 17 with ulcerative colitis (UC) and two with Crohn's disease (CD); nine had cancer and 10 had dysplasia. Controls included 25 with UC and 10 with CD. Individually, BMP3, vimentin, EYA4 and NDRG4 markers showed high discrimination in stools with respective areas under the ROC curve of 0.91, 0.91, 0.85 and 0.84 for total IBD‐CRN and of 0.97, 0.97, 0.95 and 0.85 for cancer. At 89% specificity, the combination of BMP3 and mNDRG4 detected 9/9 (100%) of CRC and 80% of dysplasia, 4/4 (100%) of high grade and 4/6 (67%) of low grade.ConclusionThese findings demonstrate the feasibility of stool DNA testing for non‐invasive detection of colorectal neoplasia associated with inflammatory bowel disease.
Regulatory Light Chain Mutants Linked to Heart Disease Modify the Cardiac Myosin Lever Arm
Sikkink, Laura A., Burghardt, Thomas P.

Mayo Clinic

Biochemistry | January 23, 2013 | Volume: 52 | Issue: 7 | Pages: 1249-1259

10.1021/bi301500d | PMID 23343568 Get It

Percutaneous Ablation of Renal Masses Measuring 3.0 cm and Smaller: Comparative Local Control and Complications After Radiofrequency Ablation and Cryoablation
Atwell, Thomas D. , Schmit, Grant D. , Boorjian, Stephen A. , Mandrekar, Jay , Weisbrod, Adam J. , Chow, George K. , Leibovich, Bradley C. , Callstrom, Matthew R. , Patterson, David E., Lohse, Christine M. , Thompson, R. Houston, Kurup, A. Nicholas

Mayo Clinic

American Journal of Roentgenology | January 23, 2013 | Volume: 200 | Issue: 2 | Pages: 461-466

10.2214/ajr.12.8618 | PMID 23345372 Get It

Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high‐risk patients
Katsolis, Jennifer , Bosch, Wendelyn , Diehl, Nancy N. , Shalev, Jefree A., Pungpapong, Surakit , Gonwa, Thomas A., Hellinger, Walter C. , Heckman, Michael G. , Pungpapong, Surakit

Mayo Clinic

Transplant Infectious Disease | January 18, 2013 | Volume: 15 | Issue: 2 | Pages: 171-180

10.1111/tid.12050 | PMID 23331429 Get It

AbstractBackgroundRecent studies have demonstrated that cytomegalovirus (CMV) infection and disease are associated with increased risk of graft loss and death in high‐risk (donor CMV seropositive/recipient CMV seronegative) liver transplant recipients (LTR) despite effective antiviral chemoprophylaxis. Predictors of CMV infection and disease in this important population are incompletely defined.MethodsA retrospective cohort study of 227 high‐risk first LTR who received primary anti‐CMV chemoprophylaxis during the first 100 days after transplant was performed. A large number of patient, donor, operative, and post‐transplant potential risk factors were collected. Associations of potential risk factors for CMV infection or disease that occurred during the first year after transplant were assessed using Cox regression models. After Bonferroni adjustment for multiple testing, P‐values ≤0.00125 (associations with CMV infection) and ≤0.00122 (associations with CMV disease) were considered as statistically significant.ResultsCMV infection and disease occurred in 91 (40%) and 43 (19%) of LTR, respectively. In multivariable analysis, increased risk of CMV infection was observed for patients with lower model for end‐stage liver disease (MELD) score (P = 0.025), lower total bilirubin (P = 0.014), and longer operative time (P = 0.038), whereas increased risk of CMV disease was seen in patients with lower MELD score (P = 0.026), lower total bilirubin (P = 0.044), and lower international normalized ratio (P = 0.043). However, after adjustment for multiple testing, none of these findings approached statistical significance.ConclusionOur results suggest that interventions designed to prevent CMV infection and disease should be applied to all high‐risk LTR until more definitive predictors of these complications are identified.
Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia
Leyhe, Thomas, Darreh‐Shori, Taher , Laske, Christoph , Mielke, Michelle M. , Maetzler, Walter , Mielke, Michelle M

Mayo Clinic

International Journal of Alzheimer's Disease | January 9, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-2

10.1155/2013/473181 | PMID 23365784 Get It

Do systolic BP and pulse pressure relate to ventricular enlargement?
Graff‐Radford, Neill R. , Penman, Alan D. , Coker, Laura H., Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

European Journal of Neurology | January 7, 2013 | Volume: 20 | Issue: 4 | Pages: 720-724

10.1111/ene.12067 | PMID 23294486 Get It

Background and purposeTo evaluate the association between systolic, diastolic and pulse pressure, and increase in ventricular size (VS). Observations in laboratory animals suggest intraventricular pulse pressure (systolic–diastolic) may play a role in ventricular enlargement.MethodsInitial magnetic resonance (MR) scans and vascular risk factors evaluation were performed in 1812 Atherosclerosis Risk in Communities participants in 1994–1995. In 2004–2006, 1130 participants underwent repeat MR. VS was rated using a validated nine‐point scale. Multiple logistic regression analysis assessed association between blood pressure measures and pulse pressure, and the change between the MR scans of VS controlling for age, sex and race.ResultsAt baseline 1112 participants (385 black women, 200 black men, 304 white women and 223 white men) had a mean age of 61.7 ± 4.3 years. In adjusted models pulse pressure at baseline was associated with an increase in VS [odds ratio (OR) 1.19, 95% confidence interval (CI) 1.01–1.40], as was systolic pressure (OR 1.28, 95% CI 1.03–1.58).ConclusionsSystolic pressure and pulse pressure are associated with future development of increased VS. The findings are consistent with the animal literature that increased pulse pressure predisposes to risk of future increased VS. High pulse pressure might play a role in the pathogenesis of normal pressure hydrocephalus.
Model-Independent Fluorescence Depolarization Studies Of Labeled Myosin Cross-Bridges In Muscle Fibers
Ajtai, Katalin , Burghardt, Thomas P.

Mayo Clinic

SPIE Proceedings | January 2, 2013 | Volume: 0909 | Issue: No issue available | Pages: 121

10.1117/12.945376 Get It